Skip to main content

Table 4 DMD utilization and patient characteristics: patients with MS in 2011

From: Updated cost-of-care estimates for commercially insured patients with multiple sclerosis: retrospective observational analysis of medical and pharmacy claims data

 

IFN beta-1a IM

IFN beta-1b

Glatiramer acetate

IFN beta-1a SC

Natalizumab

Total

All DMD users—n (%)a

1,827 (22.4)

902 (11.1)

3,261 (40.0)

1,725 (21.1)

800 (9.8)

8,145

DMD monotherapy users—n (%)

1,718 (22.0)

842 (10.8)

3,029 (38.8)

1,544 (19.8)

672 (8.6)

7,805

Characteristics of DMD monotherapy users in 2011

  
 

IFN beta-1a IM

IFN beta-1b

Glatiramer acetate

IFN beta-1a SC

Natalizumab

P value

Demographics

Gender n (%)b,c

 

0.002

 Female

1,313 (76.4)

622 (73.9)

2,354 (77.7)

1,122 (72.7)

501 (74.6)

 

 Male

404 (23.5)

220 (26.1)

675 (22.3)

422 (27.3)

171 (25.4)

 

Mean [SD] ageb

49.6 [10.1]

47.5 [11.1]

47.3 [11.0]

45.2 [10.5]

45.6 [10.1]

< 0.001

Mean [SD] DMD claimsb,d

9.21 [4.34]

9.09 [3.91]

5.95 [4.14]

9.03 [4.10]

8.92 [3.98]

< 0.001

Mean [SD] days supplyb,d

274.6 [93.4]

265.3 [95.5]

186.3 [122.3]

260.9 [105.2]

241.3 [107.8]

< 0.001

Mean [SD] days until DMD startb,d

45.80 [67.49]

41.57 [62.24]

76.43 [93.28]

54.17 [77.80]

49.05 [74.87]

< 0.001

Disease sequelaeb

  

 Abnormality of gait

104 (6.1)

80 (9.5)

247 (8.2)

133 (8.6)

107 (15.9)

< 0.001

 Ataxia

20 (1.2)

26 (3.1)

68 (2.2)

37 (2.4)

29 (4.3)

< 0.001

 Burning, numbness, tingling sensations

160 (9.3)

80 (9.5)

305 (10.1)

174 (11.3)

94 (14.0)

0.008

 Convulsions

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

NA

 Depression

125 (7.3)

74 (8.8)

279 (9.2)

143 (9.3)

90 (13.4)

< 0.001

 Fecal incontinence

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

NA

 Fibromyalgia/myalgia and myositis

26 (1.5)

15 (1.8)

84 (2.8)

27 (1.7)

24 (3.6)

0.003

 Malaise and fatigue

209 (12.2)

137 (16.3)

493 (16.3)

261 (16.9)

187 (27.8)

< 0.001

 Optic neuritis

2 (0.1)

2 (0.2)

4 (0.1)

2 (0.1)

2 (0.3)

0.809

 Spasms

33 (1.9)

23 (2.7)

73 (2.4)

39 (2.5)

37 (5.5)

< 0.001

 Trigeminal neuralgia

14 (0.8)

5 (0.6)

30 (1.0)

15 (1.0)

9 (1.3)

0.621

 Urinary incontinence

31 (0.2)

21 (0.2)

61 (2.0)

23 (1.5)

29 (4.3)

< 0.001

 Voice disturbance

4 (0.2)

0 (0.0)

6 (0.2)

1 (0.1)

2 (0.3)

0.449

MS charge components b

Mean [SD] ($)

% of Total

Mean [SD] ($)

% of Total

Mean [SD] ($)

% of Total

Mean [SD] ($)

% of Total

Mean [SD] ($)

% of Total

P value

 Inpatiente

2,061 [12,706]

4.5

3,093 [15,185]

6.4

3,053 [18,590]

7.9

2,557 [14,226]

5.6

3,610 [17,308]

4.4

0.155

 Outpatiente

6,485 [18,322]

14.2

7,931 [27,432]

16.3

7,736 [19,461]

20.1

7,540 [22,866]

16.4

23,702 [26,046]

29.0

< 0.001

 Emergency roome

15 [323]

0.0

7 [97]

0.0

27 [374]

0.1

28 [364]

0.1

60 [651]

0.1

0.059

 DMD

37,209 [13,042]

81.3

37,498 [14,007]

77.3

27,694 [18,055]

71.9

35,803 [14,766]

78.0

54,255 [34,102]

66.5

< 0.001

 Total

45,770[25,674]

100.0

48,529 [33,932]

100.0

38,509 [32,570]

100.0

45,928 [30,434]

100.0

81,627 [42,528]

100.0

< 0.001

  1. aCounts (%) sum to more than the total DMD user cohort size (100%) because patients could be treated with more than 1 DMD during the year.
  2. bCalculated for patients using a single DMD during 2011 (n = 7,805).
  3. cTable and chi-square test exclude 1 patient treated with IFN beta-1a with missing gender information.
  4. dIncludes both medical and pharmacy claims. Days until DMD start represents the number of days from January 1, 2011, until the date of the first DMD claim. For medical claims, days supply was estimated based on the expected dosing schedule for each DMD (count of injections × interval based on dosing schedule).
  5. eCharges for medical claims with an MS diagnosis (ICD-9-CM = 340.xx in any diagnosis field or a DRG code for MS).
  6. DMD = disease-modifying drug; IFN = interferon; IM = intramuscular; MS = multiple sclerosis; SC = subcutaneous; SD = standard deviation.